Aktuellt
SENASTE
Redeye is encouraged to learn that Vicore’s digital therapy “Almee” reduced anxiety by almost 50% in a pilot study (n=10) on IPF patients, an early indication of a clinically meaningful treatment effect. The next stage of the trial is the pivotal phase (n=250), expected to start in Q4. We currently don’t include Almee in our valuation, but see synergies from the program that include an increased understanding of the disease (IPF) and better interactions with patients, patient organizations, and physicians.
LÄS MER
